ORNI Oragenics Inc. featured news, full reports, and detailed charts
Oragenics Inc. (ORNI/ORNI.OB) Wrap Up:
Oragenics, Inc. operates as an early-stage biotechnology company in the United States. It primarily focuses on developing technologies associated with oral health, broad spectrum antibiotics, and other general health benefits. The company develops SMaRT Replacement Therapy, which is a painless topical treatment for protection against tooth decay; and Mutacin 1140, an antibiotic with antimicrobial activity against gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus. It also develops Probiora3, an oral probiotics technology that employs three natural strains of beneficial bacteria, which promote oral health; and IVIAT and CMAT technologies tha...Oragenics Inc. (ORNI:OTC Bulletin Board Market)
Snapshot of Oragenics Inc. (ORNI)
|
OPEN
$0.26
|
PREVIOUS CLOSE
$0.26
|
|
|
DAY HIGH
$0.30
|
DAY LOW
$0.24
|
|
|
52 WEEK HIGH
07/13/09 - $0.51
|
52 WEEK LOW
05/12/09 - $0.05
|
|
|
MARKET CAP
22.7M
|
AVERAGE VOLUME 3 mo
34.5K
|
|
|
DILUTED EPS TTM
$-0.18
|
SHARES OUTSTANDING
90.9M
|
|
|
ORNI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ORNI Top Compensated Officers
Executives, Board Directors
Key developments for Oragenics Inc. (ORNI)
Oragenics Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported loss from operations of $1,459,139 against $1,153,200 a year ago. Loss before income taxes was $1,437,008 against $1,138,117 a year ago. Net loss was $1,437,008 or $0.02 per basic and diluted share on revenues of $199,675 against net loss of $1,138,117 or $0.03 per basic and diluted share on revenues of $100,000 a year ago. For the nine months, the company reported loss from operations of $5,026,502 against $3,065,848 a year ago. Loss before income taxes was $4,286,582 against $3,024,865 a year ago. Net loss was $4,286,582 or $0.08 per basic and diluted share on revenues of $365,842 against net loss of $3,024,865 or $0.09 per basic and diluted share on revenues of $225,000 a year ago. Net cash used in operating activities was $4,413,596 against $2,331,553 a year ago. Purchase of property and equipment, net was $9,074 against $51,408 a year ago.
Oragenics Inc. announced that at the company's Annual meeting of shareholders held on October 28, 2009, the shareholders voted to authorize an amendment to its Articles of Incorporation to increase authorized common shares from 100 million shares to 300 million. All other provisions of the Articles of Incorporation remained in full force and effect. The Amended Articles of Incorporation have been filed with the Secretary of State of Florida.
Oragenics Inc. has launched Teddy's Pride(TM), the first-ever all-natural probiotics breath freshener and teeth whitener created especially for dogs and cats. Daily use of Teddy's Pride Pet Oral Care provides a quick, simple and effective way to naturally promote fresher breath and whiter teeth without the hassle, stress and poor results of trying to brush your pets' teeth or investing in costly and potentially dangerous cleaning procedures requiring anesthesia at the veterinarian's office. Simply sprinkling Teddy's Pride Pet Oral Care--which has no taste and no odor--on pets' food once each day ensures that they will have naturally fresher breath and cleaner, whiter teeth. The key active ingredient in Teddy's Pride is ProBiora3(TM), the science that was researched and developed by Oragenics to combat destructive bacteria, keep teeth white and freshen breath. By binding to the teeth, ProBiora3's beneficial bacteria leave no room or nutrients for the destructive bacteria to inhabit a healthy oral cavity. The result is a direct reduction in the volatile sulfur compounds responsible for bad breath. As an additional core benefit of ProBiora3, Teddy's Pride delivers 24-hour teeth-whitening protection for pets.
ORNI Competitors
| Company | Last | Change |
| BioGaia AB | kr80.75 SEK | -0.25 |
| Colgate Palmolive Co | $83.97 USD | -0.45 |
| Cubist Pharmaceuticals Inc | $16.95 USD | -0.10 |
| DENTSPLY International Inc | $32.86 USD | -0.29 |
| Pfizer Inc | $18.36 USD | +0.25 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ORNI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 35.4x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 71.9x |
|
|
ORNI |
||
ORNI transactions
| Type Date |
Target |
|
Private Placement
June 29, 2009 |
-- |
